<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012306</url>
  </required_header>
  <id_info>
    <org_study_id>V1.0_01-MAR-2021</org_study_id>
    <nct_id>NCT05012306</nct_id>
  </id_info>
  <brief_title>Covid-19 Antibody Responses in Cystic Fibrosis</brief_title>
  <acronym>CAR-CF</acronym>
  <official_title>Corona-Virus-Disease 2019 (Covid-19) Antibody Responses in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Köln</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus disease 2019 (COVID-19) which is caused by the virus Severe Acute Respiratory&#xD;
      Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in an ongoing global pandemic. It is unclear&#xD;
      whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is&#xD;
      due to enhanced infection prevention practices or whether pwCF have protective genetic/immune&#xD;
      factors. This study aims to prospectively assess the proportion of pwCF, including both&#xD;
      adults and children with CF who have evidence of SARS-CoV-2 antibodies over a two-year&#xD;
      period. This study will also examine whether pwCF who have antibodies for SARS-CoV-2 have a&#xD;
      different clinical presentation and what impact this has on their CF disease. The proposed&#xD;
      study will recruit pwCF from paediatric and adult CF centres throughout the United Kingdom.&#xD;
      Serological testing to detect antibodies will be performed on blood samples taken at month 0,&#xD;
      6, 12, 18 and 24 with additional time-points if bloodwork is available via normal clinical&#xD;
      care. Clinical data on, lung function, CF-related medical history, pulmonary exacerbations,&#xD;
      antibiotic use, and microbiology and vaccination receipt, will be collected during routine&#xD;
      clinical assessments.&#xD;
&#xD;
      Associations will be examined between socio-demographic and clinical variables and serologic&#xD;
      testing. The investigators will also examine the effects of SARS-CoV-2 infection on clinical&#xD;
      outcomes and analyse end-points to explore any age-related or gender-based differences, as&#xD;
      well as subgroup analysis of outcomes in lung-transplant recipients and pwCF receiving cystic&#xD;
      fibrosis transmembrane conductance regulator (CFTR) modulator therapies. As pwCF receive&#xD;
      COVID-19 vaccination the investigators will perform a comparison of the development and&#xD;
      progression of anti-SARS-CoV-2 antibodies in pwCF following natural infection and vaccination&#xD;
      SARS-CoV-2 over time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, longitudinal cohort study in people with Cystic Fibrosis (pwCF) that&#xD;
      involves repeated serial sampling of participants. This study design was chosen to provide&#xD;
      comprehensive information on SARS-CoV-2 seroprevalence changes over time and the subsequent&#xD;
      clinical impact on pwCF. The study will be conducted at participating CF centres over a&#xD;
      3-year period. Study participants will include paediatric and adult pwCF. For the United&#xD;
      Kingdom (UK) section of the study, UK investigators in the European Cystic Fibrosis&#xD;
      Society-Clinical Trials Network (ECFS-CTN) will be invited to participate. Participating&#xD;
      investigators can enrol all eligible pwCF over a 12-month period. Participants are then&#xD;
      followed up for 24 months. Participants will donate blood samples at their routine clinic&#xD;
      visits. Blood samples will be collected at Day 0 (baseline), at Months 6, 12, 18 and 24 (to&#xD;
      coincide with routine clinical reviews). Additional blood samples will be taken&#xD;
      opportunistically every time the participant visits the clinic for blood draws. These blood&#xD;
      samples could be related to, routine care, annual review visits, pulmonary exacerbations&#xD;
      (PEx), CF complications or when initiating new treatments (e.g. CFTR modulators).&#xD;
&#xD;
      Serum from blood samples will be shipped to a central laboratory (Queen's University Belfast)&#xD;
      for standardized measurement of SARS-CoV-2 antibodies.&#xD;
&#xD;
      Alongside the blood samples the investigator will also collect clinical data from the&#xD;
      patient's health records and will input this data into the case report form (CRF). Clinical&#xD;
      data will be collected in conjunction with routine care visits, according to local clinical&#xD;
      practice. Investigators will collect data elements from information routinely recorded in the&#xD;
      patients' medical records. Data will be collected at baseline, month 6, 12, 18 and 24 as per&#xD;
      the study schedule, and at additional blood sampling timepoints as previously explained&#xD;
      above. Data collection will include routine data available from CF clinic follow-ups&#xD;
      including background demographic information, CF medical history, medications, exacerbation&#xD;
      information, sputum microbiology and clinical and lung function parameters. Information on&#xD;
      SARS-CoV-2 infection history and vaccine receipt will also be collected.&#xD;
&#xD;
      The maximum follow-up duration of participation in the study for each patient will be 24&#xD;
      months. This study duration (24-month follow-up) is justified as it provides sufficient time&#xD;
      to observe changes in antibody prevalence over the course of the COVID-19 pandemic as well as&#xD;
      sufficient time to determine long term clinical outcomes for pwCF who are SARS-CoV-2&#xD;
      seropositive. Furthermore, the investigators anticipate the 2-year study follow-up period&#xD;
      will provide sufficient time to observe the impact of vaccination on antibody levels given&#xD;
      that a number of vaccines are now commercially available.&#xD;
&#xD;
      The investigators will compare the level of antibody responses between natural COVID-19&#xD;
      infection and vaccination in pwCF and how this varies over time. This will be achieved by&#xD;
      analyzing seroprevalence and antibody levels according to natural infection and vaccination&#xD;
      status and according to time of sample post infection or post vaccination, if known.&#xD;
&#xD;
      Optional Study sample collection:&#xD;
&#xD;
      For participants who consent, a second blood sample will also be drawn into Ethylenediamine&#xD;
      tetraacetic acid (EDTA) tubes (plasma). Consent to this optional study sample would allow&#xD;
      this sample and any remaining serum (following antibody testing) to be stored for future&#xD;
      analysis and allow further research to be carried out on related studies to COVID-19 and CF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate SARS-CoV-2 seroprevalence</measure>
    <time_frame>3-year period (comprising a 1-year enrollment period and a 2-year follow-up)</time_frame>
    <description>To evaluate SARS-CoV-2 seroprevalence in a cohort of people with cystic fibrosis, followed longitudinally over a 3-year period (comprising a 1-year enrollment period and a 2-year follow-up). [ Time Frame: 3-year period (comprising a 1-year enrollment period and a 2-year follow-up) ] To examine the associations between SARS-CoV-2 seropositivity, clinical symptoms and clinical outcomes in a cohort of people with cystic fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Storage of samples for future analysis</measure>
    <time_frame>anticipated 5-10 years</time_frame>
    <description>Storage of samples for future analysis on the impact of COVID-19 immune response in people with cystic fibrosis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cystic Fibrosis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants already enrolled in a clinical trial are eligible for enrolment in this study.&#xD;
        Inclusion in CAR-CF should not preclude enrolment in other observational clinical trial&#xD;
        studies or clinical trials of an investigational medicinal product (CTIMP).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Consenting people with cystic fibrosis of any age, genotype, transplant status and disease&#xD;
        severity will be eligible to participate in the study. The study population is expected to&#xD;
        be representative of the general CF population.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There are no specific exclusion criteria other than refusal to give informed consent, or&#xD;
        contraindication to venepuncture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silke van Koningsbruggen-Rietschel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CF Center, University Hospital, University of Cologne, Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silke van Koningsbruggen-Rietschel, MD, PhD</last_name>
    <phone>+49-221-478-4492</phone>
    <email>Silke.vanKoningsbruggen@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meike Meyer, MD</last_name>
    <phone>+49-221-478-42128</phone>
    <email>Meike.Meyer@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School, Clinic for Pediatric Pneumology, Allergology and Neonatology &amp; Clinic for Pneumology, Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tina Büttner, M.Sc.</last_name>
      <phone>+49-1761-532-7801</phone>
      <email>buettner.tina@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Anna-Maria Dittrich, MD</last_name>
      <phone>+49-1761-532-9785</phone>
      <email>Dittrich.anna-maria@mh-hannover.de</email>
    </contact_backup>
    <investigator>
      <last_name>Anna-Maria Dittrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix C Ringshausen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Bochum, Paediatric Pneumology and CF Center</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boeger Sandra</last_name>
      <phone>+49-234-509-6650</phone>
      <email>Sandra.boeger@klinikum-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Veronika Baumeister</last_name>
      <phone>+49-234-509-2664</phone>
      <email>veronika.baumeister@klinikum-bochum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Folke Brinkmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Schlegtendal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CF Center, University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra E Zimmermann, PhD</last_name>
      <phone>+49-221-478-40689</phone>
      <email>sandra.zimmermann@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Petra Uhlherr</last_name>
      <phone>+49-221-478-42129</phone>
      <email>Petra.Uhlherr@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Silke van Koningsbruggen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meike Meyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Pulmonology and Sleep Medicine, Cystic Fibrosis Center, Children's Hospital, University of Duisburg-Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florian Stehling, MD</last_name>
      <phone>+49-201-723-1629</phone>
      <email>florian.stehling@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Nadine Kordt</last_name>
    </contact_backup>
    <investigator>
      <last_name>Florian Stehling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathis Steindor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarete Olivier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik, Westdeutsches Lungenzentrum gGmbH</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sivagurunathan Sutharsan, MD</last_name>
      <phone>+49-201-433-4503</phone>
      <email>sivagurunathan.sutharsan@rlk.uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Dreher</last_name>
      <phone>+49-201-433-4849</phone>
      <email>sandra.dreher@rlk.uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Sivagurunathan Sutharsan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Welsner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Svenja Straßburg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt a.M., Allergologie, Pneumologie &amp; Mukoviszidose</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inge Wortmann</last_name>
      <phone>+49-69-6301-6337</phone>
      <email>inge.wortmann@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Enders</last_name>
      <phone>+49-69-6301-84301</phone>
      <email>kristina.endres@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Olaf Eickmeier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Gleiber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Jena, Cystic Fibrosis Centre for children and adults</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anika Nader</last_name>
      <phone>+49 3641 390842</phone>
      <email>anika.nader@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Katja Erler</last_name>
      <phone>+49 3641 390842</phone>
      <email>katja.erler@med.uni-jena.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Lorenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Moeser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cystic Fibrosis Center for Adults, Department of Pneumology</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanne Nährig, MD</last_name>
      <phone>+49-89-4400-57546</phone>
      <email>Susanne.Naehrig@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Judith Märkl</last_name>
      <phone>+49-89-4400-52209</phone>
      <email>judith.maerkl@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Susanne Nährig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

